24H Stock Overview
A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.33 |
| 52 Week High | SEK 4.80 |
| 52 Week Low | SEK 1.73 |
| Beta | 1.65 |
| 1 Month Change | 34.76% |
| 3 Month Change | 6.97% |
| 1 Year Change | -2.26% |
| 3 Year Change | -52.50% |
| 5 Year Change | -80.69% |
| Change since IPO | -88.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 24H | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.1% | 0.6% | 1.7% |
| 1Y | -2.3% | -12.2% | 12.8% |
Return vs Industry: 24H exceeded the German Biotechs industry which returned -13.8% over the past year.
Return vs Market: 24H underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| 24H volatility | |
|---|---|
| 24H Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 24H's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 24H's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 138 | Renee Aguiar-Lucander | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.
Hansa Biopharma AB (publ) Fundamentals Summary
| 24H fundamental statistics | |
|---|---|
| Market cap | €159.80m |
| Earnings (TTM) | -€57.29m |
| Revenue (TTM) | €16.63m |
9.6x
P/S Ratio-2.8x
P/E RatioIs 24H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 24H income statement (TTM) | |
|---|---|
| Revenue | SEK 181.68m |
| Cost of Revenue | SEK 85.93m |
| Gross Profit | SEK 95.76m |
| Other Expenses | SEK 721.50m |
| Earnings | -SEK 625.74m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 17, 2025
| Earnings per share (EPS) | -9.23 |
| Gross Margin | 52.71% |
| Net Profit Margin | -344.41% |
| Debt/Equity Ratio | -161.1% |
How did 24H perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 08:40 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansa Biopharma AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Christian Lee | ABG Sundal Collier Sponsored |
| Madhu Kumar | B. Riley Securities, Inc. |